Drug intelligence / Profile preview

PLX0206

Development stage: Preclinical
Lead developer: Cogent Biosciences
Modality: Small Molecules

Overview

PLX0206 is a preclinical-stage, selective tyrosine kinase inhibitor targeting the KIT (CD117) protein. Originally developed by Plexxikon, the asset was licensed to Kiq Bio, which was subsequently acquired by Cogent Biosciences. PLX0206 is designed to treat genetically defined diseases driven by KIT mutations, such as gastrointestinal stromal tumors (GIST) and systemic mastocytosis. It is part of a precision medicine portfolio that includes the clinical-stage KIT inhibitor bezuclastinib (PLX9486).

Other names: CGT0206CGT-0206CGT 0206PLX-0206PLX0206PLX 0206

Targets

KIT (c-KIT proto-oncogene receptor tyrosine kinase)

Beyond the preview

Go deeper on PLX0206.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PLX0206.

Explore the full profile